Chicago, ILNCT07277660Now EnrollingIRB Ready

Atopic Dermatitis Clinical Trial in Chicago, IL

Access cutting-edge atopic dermatitis treatment through this clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by UCB Biopharma SRL

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access atopic dermatitis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related atopic dermatitis treatment provided free

Apply for This Chicago Location

Check if you qualify for this atopic dermatitis clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Atopic Dermatitis Study in Chicago

The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).

Sponsor: UCB Biopharma SRL

Who Can Participate

Inclusion Criteria

Participant must be aged greater than or equal (≥)18 years at the time of signing the informed consent
Participant has chronic atopic dermatitis (AtD) (according to American Academy of Dermatology Consensus Criteria) that has been present for at least ≥1 year prior to initiating the study (ie, signing of the informed consent form \[ICF\]) and with:
validated Investigator Global Assessment (vIGA) score ≥3 at Screening and Baseline
Eczema Area and Severity Index (EASI) score ≥16 at both Screening and Baseline
Peak Pruritus Numerical Rating Scale (PP-NRS) score of ≥4 at both Screening and Baseline
≥10% body surface area (BSA) of AtD involvement at both Screening and Baseline
Documented recent history (within 6 months prior to Screening) of inadequate response to treatment with topical medications, or study participants for whom topical treatments are otherwise medically inadvisable (eg, due to important side effects or safety risks) and who are candidates for systemic therapy

Exclusion Criteria

Participant has any history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, or electrocardiogram (ECG) signal that, in the opinion of the investigator, could constitute a risk when taking the study intervention; or interfere with the interpretation of data and could jeopardize or would compromise the study participant's ability to participate in this study
Active dermatologic conditions that may confound the diagnosis of AtD or would interfere with assessment of treatment, such as but not limited to scabies, seborrheic dermatitis, cutaneous lymphoma, ichthyosis, psoriasis, active allergic or irritant contact dermatitis
Presence or family history (first degree) of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
History of chronic or recurrent infections, or a serious or life-threatening infection within the 6 months prior to the Baseline (including herpes zoster) as judged by the investigator
Participants are not permitted to enroll into the study if they meet tuberculosis (TB) exclusion criteria
Previous treatment with galvokimig
Participant has relevant safety events to one or more interleukin (IL)-13 biologic response modifiers (ie, dupilumab, tralokinumab and lebrikizumab) that resulted in discontinuation and change of treatment
All systemic therapies (other than biologics), topical therapies and other treatments for AtD must be discontinued at least 4 weeks prior to Baseline
Treatment with biologic agents must discontinued at least 3 months prior to baseline

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT07277660) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Atopic Dermatitis Treatment Options in Chicago, IL

If you're searching for atopic dermatitis treatment options in Chicago, IL, this clinical trial (NCT07277660) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this clinical trial. You'll receive care from experienced atopic dermatitis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all atopic dermatitis clinical trials near you to find additional studies recruiting in your area.

More Atopic Dermatitis Trials in Chicago, IL

See all atopic dermatitis clinical trials recruiting in Chicago — not just this study.

Browse Atopic Dermatitis Trials in Chicago →

Browse More Trials by Condition

Atopic Dermatitis TrialsInterstitial Cystitis TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL